Adagene's Price Target Adjusted Down to $7.00 by HC Wainwright Amidst Analyst Ratings
ByAinvest
Sunday, Aug 17, 2025 12:43 pm ET1min read
ADAG--
The revised price target reflects a 12.50% decrease, aligning with recent regulatory milestones and strategic partnerships. Adagene's recent FDA meeting provided clarity on the development path for its lead program, muzastotug (ADG126), which is now in Phase 2 trials in combination with pembrolizumab for microsatellite stable colorectal cancer (MSS-CRC) patients [2].
The average target price for ADAG is $9.64, with a high estimate of $21.07 and a low estimate of $3.50. This average target implies an upside of 379.73% from the current price of $2.01. Other analysts have also shown interest in ADAG, with Leerink Partners initiating coverage with an "outperform" rating and a $7.00 price target [1].
Investors should consider the recent developments, including strategic partnerships and clinical trial advancements, when evaluating Adagene's potential. The company's debt-to-equity ratio of 0.01 and strong liquidity ratios (current ratio of 2.29, quick ratio of 2.30) indicate a solid financial position [1].
References:
[1] https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-pessimistic-forecast-for-adagene-nasdaqadag-stock-price-2025-08-15/
[2] https://www.investing.com/news/analyst-ratings/hc-wainwright-lowers-adagene-stock-price-target-to-7-on-development-path-clarity-93CH-4195188
Adagene (ADAG) analyst ratings maintain 'Buy' with a price target adjusted from $8.00 to $7.00 USD, a 12.50% decrease. HC Wainwright & Co. analyst Arthur He made this revision, and the average target price for ADAG is $9.64 with a high estimate of $21.07 and a low estimate of $3.50. The average target implies an upside of 379.73% from the current price of $2.01.
Adagene Inc. (NASDAQ: ADAG) has seen a revision in its analyst ratings, with HC Wainwright & Co. analyst Arthur He lowering the price target from $8.00 to $7.00 USD. Despite this adjustment, the stock maintains a "buy" rating, indicating a potential upside of 248.26% based on the current price of $2.01 [1].The revised price target reflects a 12.50% decrease, aligning with recent regulatory milestones and strategic partnerships. Adagene's recent FDA meeting provided clarity on the development path for its lead program, muzastotug (ADG126), which is now in Phase 2 trials in combination with pembrolizumab for microsatellite stable colorectal cancer (MSS-CRC) patients [2].
The average target price for ADAG is $9.64, with a high estimate of $21.07 and a low estimate of $3.50. This average target implies an upside of 379.73% from the current price of $2.01. Other analysts have also shown interest in ADAG, with Leerink Partners initiating coverage with an "outperform" rating and a $7.00 price target [1].
Investors should consider the recent developments, including strategic partnerships and clinical trial advancements, when evaluating Adagene's potential. The company's debt-to-equity ratio of 0.01 and strong liquidity ratios (current ratio of 2.29, quick ratio of 2.30) indicate a solid financial position [1].
References:
[1] https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-pessimistic-forecast-for-adagene-nasdaqadag-stock-price-2025-08-15/
[2] https://www.investing.com/news/analyst-ratings/hc-wainwright-lowers-adagene-stock-price-target-to-7-on-development-path-clarity-93CH-4195188
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet